Abstract. Protein phosphatase, Mg\(^{2+}\)/Mn\(^{2+}\) dependent, 1D (PPM1D) has been associated with carcinogenesis. The present study investigated PPM1D expression as a potential biomarker in colorectal cancer (CRC). PPM1D expression was assessed using immunohistochemistry in 368 patients with CRC. The correlation between PPM1D expression, clinicopathological features and prognosis was analyzed. PPM1D small interfering (si)RNA-induced PPM1D silencing was performed in CRC cell lines to assess the effect of PPM1D on tumor cell proliferation and invasion in vitro. A total of 68.48% (252/368) of the CRC samples displayed high PPM1D expression. By contrast, only 9.24% (34/368) of the matched non-cancerous tissue samples exhibited high PPM1D expression. High PPM1D expression was correlated with node metastasis (P=0.0024), distant metastasis (P<0.001) and TNM stage (P=0.0016). Kaplan-Meier survival analysis revealed that patients with low PPM1D expression had significantly longer survival than those with high PPM1D expression (P=0.012). Moreover, multivariate analyses demonstrated that high PPM1D expression was an independent prognostic factor for overall survival (hazard ratio = 0.24; 95% confidence interval, 0.13-0.86; P=0.004). Furthermore, PPM1D gene silencing was found to significantly reduce the proliferation and invasion of CRC cells in vitro. These findings suggest a role for PPM1D as a prognostic marker and potential therapeutic target in CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer in humans worldwide (1). It has recently been reported that CRC mortality accounts for ~9% of all cancer mortalities (2). The survival rate for CRC is higher at early stages following surgical resection; however, the long-term survival rate and prognosis for patients with CRC remain poor (3). Currently available cancer markers are not suitable for current clinical practice and require further investigation. Therefore, there is an urgent requirement for the discovery of novel targets and useful biomarkers for CRC prognosis.

Protein phosphatase, Mg\(^{2+}\)/Mn\(^{2+}\) dependent, 1D (PPM1D) is a member of the protein phosphatase 2C family and is involved in a wide range of physiological functions, including cell signaling, apoptosis and the cell cycle (4). A growing body of evidence suggests that PPM1D is involved in tumorigenesis. PPM1D has been reported to be upregulated in human primary breast, ovarian and neuroblastoma tumors (5-7). Of note, PPM1D has been found to complement oncogenes during cellular transformation (8). However, the role of PPM1D in CRC is yet to be elucidated. The present study investigated the expression pattern and clinical significance of PPM1D in CRC, including the correlation of PPM1D with clinical outcome.

Materials and methods

Patients and samples. Based on tissue data availability, 368 cases of CRC, between 2003 and 2007, were included in the present study. Clinicopathological features of the patients with CRC are shown in Table I. Formalin-fixed paraffin-embedded tissues were collected from the Second and First Affiliated Hospitals of Hunan University of Chinese Medicine (Changsha, China). This study was approved by the Ethics Committees of Hunan University of Chinese Medicine. Informed consent was obtained from all participants and the study was performed in accordance with the Declaration of Helsinki. Follow-up data were obtained from medical records and direct communication with the patients or their relatives. The follow-up period was defined as the time from the date of surgery to the date of patient mortality or the final follow-up in January 2012.

Histopathological evaluation and scoring. Paraffin-embedded serial sections of CRC specimens were analyzed for PPM1D protein expression using an anti-PPM1D antibody (Abcam,
Immunostaining was assessed by two independent, blinded pathologists and scored by multiplying the intensity of the staining by the percentage of stained cells. The staining intensity was graded on a scale of 0 to 3. The percentage of stained tumor cells was graded as follows: 0 (<5%), 1 (5-25%), 2 (26-50%), 3 (51-75%) and 4 (>75%). The final scores ranged from 0 to 12. For any subsequent analysis, scores between 0 and 4 were defined as low expression and those between 5 and 12 were defined as high expression (11). Inconsistent scores were re-evaluated by two pathologists until a consensus score was established.

Quantitative polymerase chain reaction (qPCR) analysis. Total RNA was extracted from cells using an RNA extraction kit (Qiagen Co., Ltd., Shanghai, China) according to the manufacturer's instructions. Total RNA was used for quantification using the One-Step RT-PCR kit (Invitrogen Life Technologies, Carlsbad, CA, USA) in a Roche Light Cycler (Roche Diagnostics, Basel, Switzerland). The primer sequences used in the study were as follows: PPM1D, 5'-CAATTGGCCCTTG TGCCTACT-3' (forward) and 5'-TCTTTCGCCTGAGGTTGTG-3' (reverse); and β-actin, 5'-CCTGTACGCCAACACAGTGC-3' (forward) and 5'-ATACTCCTGCTTGCAGTACC-3' (reverse). The PCR cycling conditions consisted of a denaturation step at 95°C for 3 min, followed by 40 cycles of 95°C for 10 sec and 60°C for 1 min. Samples were normalized using β-actin mRNA expression and relative expression was calculated using the ΔΔCt method.

Western blot analysis. Cells were lysed in lysis buffer and protein concentrations were measured using a BCA protein assay kit (Qiagen Co., Ltd.). Total protein was separated using SDS-PAGE on a 12.5% gel and electroblotted onto polyvinylidene fluoride membranes (Millipore Corporation, Billerica, MA, USA). Membranes were immunoblotted overnight at 4°C with primary antibodies against human PPM1D (1:1,000 dilution; Sigma-Aldrich, St. Louis, MO, USA) or β-actin (1:2,000 dilution; Sigma-Aldrich). Following three washes with Tris-buffered saline containing Tween 20, membranes were incubated with horseradish peroxidase-conjugated IgG secondary antibodies (1:2,000 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 2 h. Immunoreactive signals were detected using an enhanced chemiluminescence detection reagent (Pierce Biotechnology, Rockford, IL, USA). Expression levels were quantified from the images using Quantity One® (Bio-Rad, Hercules, CA, USA). All experiments were performed in triplicate.

Cell culture and transfection. HCT-116, RKO and COLO-320 CRC cell lines were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in RPMI-1640 in 5% CO2 at 37°C. PPM1D siRNA and scrambled siRNA were purchased from Invitrogen Life Technologies and transfected using Lipofectamine® 2000 (Invitrogen Life Technologies) according to the manufacturer's instructions.

MTT assay. Cell viability was assessed using an MTT assay. Following transfection, cells were plated in 96-well plates and incubated for 24, 48 and 72 h. A total of 20 μl 5 mg/ml MTT (Sigma-Aldrich) was added to each corresponding test well and incubated for 4 h at 37°C. The supernatant was then discarded and 200 μl dimethyl sulfoxide was added to each well to dissolve the formazan. Optical density was assessed by measuring the absorbance of each well at 490 nm using a spectrophotometer (SpectraMax Plus384; Molecular Devices, Sunnyvale, CA, USA). All experiments were performed in triplicate.

Cell invasion assay. At 12 h after transfection, the mixed medium containing Lipofectamine 2000 was discarded and cells were maintained in serum-free RPMI-1640 medium overnight. Cell invasion was then assessed using a 24-well Cell Invasion assay (BD Biosciences, San Jose, CA, USA) with 8 μm pores according to the manufacturer's instructions. Cells were

---

**Table I. Clinicopathological characteristics and PPM1D expression in patients with colorectal cancer.**

| Characteristic          | n  | Low | High | P-value |
|-------------------------|----|-----|------|---------|
| Total                   | 368| 116 | 252  |         |
| Age (years)             |    |     |      | 0.371   |
| <60                     | 144| 52  | 92   |         |
| ≥60                     | 224| 64  | 160  |         |
| Gender                  |    |     |      | 0.49    |
| Male                    | 208| 72  | 136  |         |
| Female                  | 160| 44  | 116  |         |
| Tumor location          |    |     |      | 0.875   |
| Right colon             | 80 | 24  | 56   |         |
| Left colon              | 92 | 32  | 60   |         |
| Rectum                  | 196| 60  | 136  |         |
| Histology (differentiation) |  |      |      | 0.098   |
| Well                    | 172| 48  | 124  |         |
| Moderate                | 136| 56  | 80   |         |
| Poor                    | 60 | 12  | 48   |         |
| Node metastasis         |    |     |      | 0.0024  |
| N0                      | 160| 72  | 88   |         |
| N1-3                    | 208| 44  | 164  |         |
| Distant metastasis      |    |     |      | <0.001  |
| No                      | 288| 112 | 176  |         |
| Yes                     | 80 | 4   | 76   |         |
| TNM stage               |    |     |      | 0.0016  |
| I                       | 28 | 12  | 16   |         |
| II                      | 112| 24  | 88   |         |
| III                     | 148| 72  | 76   |         |
| IV                      | 80 | 8   | 72   |         |

PPM1D, protein phosphatase, Mg2+/Mn2+ dependent, 1D.
incubated for 72 h. The upper compartment was coated with 50 µg Matrigel™ (BD Biosciences) and the lower compartment was filled with medium containing 10% fetal calf serum as a chemoattractant. Spectrophotometry was conducted using a microtiter plate reader (SpectraMax Plus384; Molecular Devices) at 540 nm. All assays were performed in triplicate.

Statistical analysis. All statistical analyses were performed using SPSS 16.0 software (SPSS, Inc, Chicago, IL, USA). The $\chi^2$ test was performed for categorical data. Kaplan-Meier estimates, log-rank tests and multivariate Cox proportional hazard regression models were performed for survival analyses. A value of $P<0.05$ was considered to indicate statistical significance.

Results

Correlation between PPM1D and clinicopathological variables. PPM1D expression was analyzed in 368 CRC tissue samples and paired non-cancerous colorectal tissue samples. Among the 368 CRC tissues, 68.48% (252/368) of cases demonstrated high PPM1D expression, while only 9.24% (34/368) of the matched, non-cancerous colorectal tissue samples showed high PPM1D expression ($P<0.001$). Immunohistochemistry revealed a predominantly nuclear localization of PPM1D (Fig. 1) and showed that PPM1D expression was significantly higher in CRC tissue than in non-cancerous, normal colorectal tissue. In addition, significant differences in PPM1D expression were observed between...
tumors with node metastasis (P=0.0024), distant metastasis (P<0.001) and different TNM stages (P=0.0016; Table I). No significant correlation was observed between PPM1D expression and patient age or gender or tumor location or histology (Table I).

PPM1D expression and survival in patients with CRC. Kaplan-Meier survival analysis revealed that the patients with low PPM1D expression had significantly longer survival than those with high PPM1D expression (log-rank, P<0.001; Fig. 2A). The correlation between metastatic lymph node
PPM1D expression and patient survival was also assessed. Kaplan-Meier analysis revealed that patients with low PPM1D expression in the metastatic lymph nodes had significantly longer overall survival than patients with high metastatic lymph node PPM1D expression (Fig. 2B, log-rank P=0.009).

Furthermore, multivariate analysis was performed using the Cox proportional hazards model. High PPM1D expression was identified to be a significant independent prognostic factor for OS (hazard ratio=0.24; 95% confidence interval, 0.13–0.86; P=0.004) as shown in Table II.

PPM1D siRNA significantly reduces CRC cell proliferation and invasion. PPM1D expression was analyzed in three CRC cell lines: HCT-116, RKO and COLO-320. PPM1D expression was observed to be higher in RKO and COLO-320 cells than in HCT-116 cells (Fig. 3A). Based on this finding, RKO and COLO-320 cells were used for the subsequent functional analysis.

siRNA-induced PPM1D knockdown was confirmed using qPCR and western blot analyses (Fig. 3B). PPM1D siRNA was observed to significantly reduce proliferation and invasion in RKO and COLO-320 CRC cells (Fig. 3C and D).

Discussion

The present study investigated the correlation between PPM1D expression, survival and clinical and pathological features in patients with CRC. Significant correlations were observed between PPM1D expression, metastasis, TNM stage and mortality. Furthermore, these correlations were found to be independent of other patient characteristics. These findings indicate that high PPM1D expression may be a useful prognostic marker for CRC.

PPM1D has been reported to be upregulated in neuroblastoma, as well as pancreatic, lung, bladder, liver, ovarian and breast cancer (6,7,12,13). However, the role of PPM1D in CRC is yet to be elucidated. In the present study, immunohistochemistry revealed that PPM1D was upregulated in CRC tissues compared with the levels in paired non-cancerous tissues. In human breast tissue, PPM1D overexpression has been found to contribute to malignant progression through inactivating wild-type p53 and p38 mitogen-activated protein kinase, as well as through decreasing p16 protein expression (14). PPM1D has also been shown to be a prognostic marker in patients with lung adenocarcinoma (15). Furthermore, high PPM1D expression has been reported to be correlated with poor prognosis in patients with pancreatic neuroendocrine tumors and medulloblastoma (16,17). In the present study, patients with CRC with high PPM1D expression were observed to have a worse outcome than those with low PPM1D expression. Furthermore, multivariate analysis suggested that high PPM1D expression was an independent prognostic factor for patients with CRC. In vitro experiments in CRC cells were also performed and revealed that PPM1D siRNA significantly inhibited CRC cell proliferation and invasion. These findings indicate that PPM1D may not only be a prognostic marker, but also a potential therapeutic target.

In conclusion, PPM1D may be a prognostic biomarker for CRC and its high expression is associated with poorer prognosis. Further investigations are required to validate the findings of the present study and to elucidate the underlying mechanisms through which PPM1D affects CRC.

References

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ and van der Burg SH: Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines 10: 899-921, 2011.
4. Lee G and Wang Y: Functional diversity of mammalian type 2C protein phosphatase isoforms: new tales from an old family. Clin Exp Pharmacol Physiol 35: 107-112, 2008.
5. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabrielle T, McCurrach ME, Marks JR, Hoey T, Lowe SW and Powers S: Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q25. Nat Genet 31: 133-134, 2002.
6. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I: Association of 17q12-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9: 1995-2004, 2003.
7. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T and Inazawa J: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876-1883, 2003.
8. Brouk DJ, Demidov ON, Fekk C, Shreeam S, Timofeev O, Fornace AJ, Appella E and Bulavin DV: The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26: 2502-2506, 2007.
9. Morikawa T, Kuchiba A, Qinan ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS and Ogino S: Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 19: 1994-1953, 2012.
10. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Noshio K, Chan AT, Giovannucci E, Fuchs CS and Ogino S: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305: 1685-1694, 2011.
11. Weichert W, Roßke A, Gekeler V, Beckers T, Ebert MP, Pross M, Dieck M, Denkert C and Röcken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148, 2008.
12. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamaizaki K, Kosuge T, Kanai Y, Hodosoda F, Imoto I, Ohki M, Inazawa J and Hiroshishi S: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400, 2007.
13. Wang P, Rao J, Yang H, Zhao H and Yang L: Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas. J Surg Oncol 104: 679-684, 2011.
14. Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G and Choi J: Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 101: 269-278, 2007.
15. Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Satoh S, Yoda M, Inazawa J and Hiroshishi S: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400, 2007.
16. Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, Brennan MF, Levine AJ, and Tang LH: Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1: 360-368, 2010.
17. Castelino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA and Kim JY: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86: 245-256, 2008.